These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34556309)

  • 1. Teprotumumab for Asymmetric Thyroid Eye Disease.
    Ugradar S; Wang Y; Douglas R
    Ophthalmology; 2021 Oct; 128(10):1416. PubMed ID: 34556309
    [No Abstract]   [Full Text] [Related]  

  • 2. Teprotumumab for Optic Neuropathy in Thyroid Eye Disease.
    Slentz DH; Smith TJ; Kim DS; Joseph SS
    JAMA Ophthalmol; 2021 Feb; 139(2):244-247. PubMed ID: 33270090
    [No Abstract]   [Full Text] [Related]  

  • 3. Teprotumumab (Tepezza) for thyroid eye disease.
    Med Lett Drugs Ther; 2021 May; 63(1625):87-88. PubMed ID: 34101720
    [No Abstract]   [Full Text] [Related]  

  • 4. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired Epiblepharon Alleviated With Teprotumumab Treatment in Active Thyroid Eye Disease Patient.
    Chen KW; Phelps PO
    Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):e195-e196. PubMed ID: 34269764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teprotumumab: First Approval.
    Markham A
    Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Case of Teprotumumab Treatment in an Adolescent Patient With Thyroid Eye Disease.
    Radulovich N; Van Brummen A; Chambers C; Zhang M
    Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):e65-e67. PubMed ID: 38231594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab for Dysthyroid Optic Neuropathy: Early Response to Therapy.
    Sears CM; Azad AD; Dosiou C; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2021 May-Jun 01; 37(3S):S157-S160. PubMed ID: 32976335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teprotumumab for the treatment of thyroid eye disease.
    Ju Y; Yang J
    Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Tocilizumab for Thyroid Eye Disease: Simplified Dosing and Delivery.
    Copperman T; Idowu OO; Kersten RC; Vagefi MR
    Ophthalmic Plast Reconstr Surg; 2019; 35(3):e64-e66. PubMed ID: 30865069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
    Slentz DH; Nelson CC; Smith TJ
    Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.
    Chu M; Sung J; Song M; Song A; Song J
    J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New-Onset of Inflammatory Bowel Disease in a Patient Treated With Teprotumumab for Thyroid Associated Ophthalmopathy.
    Ashraf DC; Jankovic I; El-Nachef N; Winn BJ; Kim GE; Kersten RC
    Ophthalmic Plast Reconstr Surg; 2021 Sep-Oct 01; 37(5):e160-e164. PubMed ID: 33710035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.
    Hoang TD; Nguyen NT; Chou E; Shakir MK
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33972303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teprotumumab for Inactive Thyroid Eye Disease? The Jury Is Still Out.
    Dosiou C
    J Clin Endocrinol Metab; 2024 Aug; 109(9):e1802-e1803. PubMed ID: 38279938
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of teprotumumab in thyroid eye disease.
    Greenhill C
    Nat Rev Endocrinol; 2021 Jul; 17(7):383. PubMed ID: 33953374
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Response to Tocilizumab in Severe Thyroid Eye Disease.
    Sy A; Eliasieh K; Silkiss RZ
    Ophthalmic Plast Reconstr Surg; 2017; 33(3):e55-e57. PubMed ID: 27281483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Teprotumumab for thyroid-associated ophthalmopathy : OPTIC].
    Gärtner R; Nitschmann S
    Internist (Berl); 2020 Nov; 61(11):1208-1210. PubMed ID: 33025123
    [No Abstract]   [Full Text] [Related]  

  • 20. Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.
    Trinh T; Haridas AS; Sullivan TJ
    Ophthalmic Plast Reconstr Surg; 2016; 32(6):e128-e129. PubMed ID: 25794019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.